Roberto Beltran
Family · Lawrence, MANPI 1942374715
Payments from drug & device makers
Across 147 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$576
- Novo Nordisk$441
- AstraZeneca$363
- Lilly USA, LLC$269
- Amgen$237
- Boehringer Ingelheim$139
- plus $940 from 18 others
What the payments were for
- Food & beverage$2,93499%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $576 |
| Novo Nordisk | 25 | $441 |
| AstraZeneca | 16 | $363 |
| Lilly USA, LLC | 14 | $269 |
| Amgen | 12 | $237 |
| Boehringer Ingelheim | 7 | $139 |
| Pfizer | 6 | $112 |
| Bayer | 5 | $103 |
| Abbott | 5 | $102 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Paratek Pharmaceuticals, Inc. | 3 | $63 |
| Novartis | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 2 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Hologic Sales And Service, LLC | 2 | $49 |
| GSK | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Johnson & Johnson | 2 | $38 |
| Exact Sciences | 1 | $30 |
| Ardelyx, Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$112
How this compares
$2,964 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 117 | $144,835 |
| OzempicSemaglutide | 80 | $98,733 |
| JardianceEmpagliflozin | 73 | $92,233 |
| MounjaroTirzepatide | 41 | $52,478 |
| LinzessLinaclotide | 48 | $34,857 |
| EliquisApixaban | 31 | $28,061 |
| FarxigaDapagliflozin Propanediol | 14 | $22,210 |
| XareltoRivaroxaban | 15 | $20,956 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $19,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,824 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,556 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,377 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,377 |
| JanuviaSitagliptin Phosphate | 13 | $6,506 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $269 | $197,312158 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $139 | $118,917104 claims |
| Novo NordiskOzempic | $441 | $98,73380 claims |
| AbbVieLinzess | $576 | $34,85748 claims |
| PfizerEliquis | $112 | $28,06131 claims |
| AstraZenecaFarxiga, Symbicort | $363 | $25,86529 claims |
| Johnson & JohnsonXarelto | $38 | $20,95615 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $47 | $19,20129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.
Other family in Lawrence
- Jennifer FlemingLawrence$80K
- Ani PavliLawrence$14K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.